Items where Funder is Bousfield Holdings Ltd.
1T01-A321
Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.
4616
Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.
C6003/A15546
Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.
C6003/A6407
Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.
Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.
C6003/A7367
Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.
C7852/A19772
Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.
NOT GIVEN
Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.
TS/S012702/1 104687
Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.